摘要
目的:胞质多聚腺苷酸化元件结合蛋白4(cytoplasmic polyadenylation element binding protein 4,CPEB4)是胞质多聚腺苷酸化元件结合蛋白家族之一,与多种肿瘤发生发展密切相关,但在非小细胞肺癌(non-small cell lung cancer,NSCLC)中的研究相对较少。方法:收集2007年6月至2012年12月郑州大学附属洛阳中心医院实施肺癌根治术102例患者临床病理资料。实时定量PCR(qRT-PCR)检测组织及细胞株中CPEB4 mRNA的表达,Western blot检测CPEB4在组织及细胞株中蛋白的表达,免疫组织化学法检测NSCLC患者石蜡标本中蛋白的表达。进一步分析CPEB4与NSCLC患者临床病理因素及预后的关系。结果:CPEB4 mRNA和蛋白(P<0.05)在NSCLC细胞株H322,H1975和A549表达明显高于WI-38正常肺细胞株,同时CPEB4 mRNA(P<0.05)和蛋白(P<0.05)在肺癌组织中高于邻近正常肺组织。免疫组织化学法检测CPEB4阳性表达率为38.2%。相关分析显示N分期为CPEB4表达的独立相关因素。预后生存分析结果显示T、N分期和CPEB4表达与本组NSCLC患者预后密切相关。结论:CPEB4在NSCLC患者中高表达,并且与预后密切相关,可作为潜在靶点。
Objective： To explore CPEB4 expression in patients with NSCLC and its prognostic value. Methods： The CPEB4 mRNA expression levels were detected by real-time quantitative PCR, while the expression levels of proteins were detected by Western blot. The protein expression in formalin-fixed samples were analyzed by immunohistochemistry. The prognostic significance of CPEB4 in NSCLC patients was investigated by Log-rank and Cox proportional hazard regression model. Results： The mRNA and protein expression levels of CPEB4 in NSCLC cell lines were both higher than those in normal lung cell line. The mRNA and protein expression levels of CPEB4 were significantly upregulated in NSCLC tissues compared to the adjacent non-tumor tissues. The CPEB4-positive expression ratio was 38.2% in the formalin-fixed samples. N stages were identified as the relative factors of CPEB4 expression （P〈0.05）. Cox multivariate analysis showed significant relationships between overall survival and T stage, and between N stage and CPEB4 expression. Conclusions： CPEB4 expression was elevated in NSCLC and was related with the prognosis. Hence, it may be a potential target in NSCLC treatment.
作者
秦爱英
任铁军
侯建锋
刘畅
单风晓
熊向乐
陈静
Aiying O.in;Tiejun Ren;Jianfeng Hou;Chang Liu;Fengxiao Shan;Xiangle Xiong;Jing Chen(The Third Department of Oncology, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang 471000, China)
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2018年第9期453-457,共5页
Chinese Journal of Clinical Oncology
